Ultragenyx Pharmaceutical Inc.
RARE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.55B
Close$
$55.30
109.6% upside
Current Fair Value
109.6% upsideUndervalued by 109.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.55 Billion |
|---|---|
| Enterprise Value | $2.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.83 |
| Beta | 0.31 |
| Outstanding Shares | 101,900,000 |
Return
| Return on Equity | 201.52% |
|---|---|
| Return on Assets | -46.39% |
| Return on Invested Capital | -56.67% |
Valuation & Multiples
| P/E Ratio | -4.44 |
|---|---|
| PEG | 22.22 |
| Price to Sales | 3.77 |
| Price to Book Ratio | -8.79 |
| Enterprise Value to Revenue | 3.49 |
| Enterprise Value to EBIT | -4.84 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-1.22
Average shareholder expectationRevenue Estimate
$183.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$183.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 71.64% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 11,400▼ 98.73% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 22.62%▼ 74.90% |
|---|---|
| Total Invested | $757.02M▼ 63.14% |
| Investors Holding | 101▼ 210.00% |
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis